How tobacco product rules affect smokers and communities
Innovative Statistical Methods for Estimating the Impact of Tobacco Product Standards
This work creates new statistical tools to estimate how lowering nicotine in cigarettes and other tobacco rules might change quitting, smoking behavior, and public health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11260247 on NIH RePORTER |
What this research studies
If you smoke or live with someone who smokes, this project aims to combine clinical trial results and large national datasets to predict how nicotine reduction and other product standards could change quitting, cigarette use, and health outcomes. The researchers will build new statistical methods to link trial findings with representative U.S. smoking data so estimates reflect the whole population. They will examine differences across demographic groups to see who benefits most and to spot possible unintended consequences. The goal is to produce realistic, population-level predictions that can inform fair and effective tobacco regulations.
Who could benefit from this research
Good fit: People who currently smoke cigarettes, people who have participated in tobacco clinical trials, or individuals whose health or survey data are part of smoking-related datasets would be most directly relevant to this work.
Not a fit: People who do not use tobacco or whose demographic groups are not represented in the available trials and datasets may not receive direct benefit from these analyses.
Why it matters
Potential benefit: If successful, this work could give regulators clearer, more accurate predictions about how product standards would reduce smoking and related harms, helping shape policies that improve public health.
How similar studies have performed: Previous randomized trials of low-nicotine cigarettes have shown effects on use and quitting, but combining trial results with population data using novel statistical methods is a relatively new and developing approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Koopmeiners, Joseph S. — University of Minnesota
- Study coordinator: Koopmeiners, Joseph S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.